

# Andrew Mark Scott

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5581203/andrew-mark-scott-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100  
papers

4,836  
citations

31  
h-index

69  
g-index

109  
ext. papers

6,015  
ext. citations

8.1  
avg, IF

5.82  
L-index

#	Paper	IF	Citations
100	Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT.. <i>Annals of Nuclear Medicine</i> , <b>2022</b> , 36, 162	2.5	0
99	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma <b>2022</b> , 1-35		
98	Automated processing of solid target Y using enriched SrO powder.. <i>Applied Radiation and Isotopes</i> , <b>2021</b> , 181, 110052	1.7	
97	Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 926-933	8.9	8
96	The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 755-756	8.9	1
95	Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1492-1494	8.9	
94	Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 884-885	8.9	0
93	Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. <i>Lung Cancer</i> , <b>2021</b> , 153, 35-41	5.9	3
92	Mediators and clinical treatment for cancer cachexia: a systematic review. <i>JCSM Rapid Communications</i> , <b>2021</b> , 4, 166-186	2.6	2
91	Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 341-350	21.7	14
90	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , <b>2021</b> , 65, 103252	8.8	5
89	Medical imaging and nuclear medicine: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e136-e172	21.7	39
88	GPA33 is expressed on multiple human blood cell types and distinguishes CD4 central memory T cells with and without effector function. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 1377-1389	6.1	
87	The value of F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 428-448	8.8	24
86	Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 422-430	8.9	7
85	Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. <i>International Journal of Rheumatic Diseases</i> , <b>2021</b> , 24, 56-62	2.3	2
84	Radiolabelling and preclinical characterization of Zr-Df-radiolabelled bispecific anti-PD-L1/TGF- $\beta$ II fusion protein bintrafusp alfa. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 3075-3088	8.8	5

83	[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 797-804	40	161
82	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. <i>Nuclear Medicine and Biology</i> , <b>2021</b> , 93, 37-45	2.1	0
81	The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1301-1311	21.7	1
80	2020 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 14N-19N	8.9	
79	Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. <i>Lung Cancer</i> , <b>2020</b> , 150, 1-8	5.9	3
78	GPA33: A Marker to Identify Stable Human Regulatory T Cells. <i>Journal of Immunology</i> , <b>2020</b> , 204, 3139-3148	3.48	11
77	Imaging of neuroinflammation in adult Niemann-Pick type C disease: A cross-sectional study. <i>Neurology</i> , <b>2020</b> , 94, e1716-e1725	6.5	6
76	Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2461-2468	8.8	9
75	Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 1476-1485	8.8	6
74	Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. <i>Blood</i> , <b>2020</b> , 136, 43-44	2.2	5
73	Automated synthesis of F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2020</b> , 5, 23	5.8	
72	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. <i>ELife</i> , <b>2020</b> , 9,	8.9	31
71	Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , <b>2020</b> , 25,	4.8	53
70	The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1089-1098	21.7	18
69	Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1077-1088	21.7	21
68	First clinical study of a pegylated diabody I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , <b>2020</b> , 10, 11404-11415	12.1	7
67	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2117-2125	6.1	11
66	2019 SNMMI Highlights Lecture: Oncology and Therapy. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 11N-17N	8.9	

65	2019 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 7N-13N	8.9	
64	2020 SNMMI Highlights Lecture: Oncology and Therapy, Part 1. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 31N-40N	8.9	
63	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10009-10018	11.5	23
62	Repurposing the selective estrogen receptor modulator to suppress gastrointestinal cancer growth. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11,	12	22
61	Assessment of Simplified Methods for Quantification of F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1221-1227	8.9	5
60	Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. <i>Theranostics</i> , <b>2019</b> , 9, 1154-1169	12.1	18
59	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 106-114	1	56
58	AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , <b>2019</b> , 134, 5332-5332	2.2	1
57	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. <i>Blood</i> , <b>2019</b> , 134, 5328-5328	2.2	1
56	ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi6-vi6	1	2
55	Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 795-805	6.1	26
54	Accuracy of Dose Calibrators for Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 636-638	8.9	22
53	Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. <i>Rheumatology</i> , <b>2018</b> , 57, 345-353	3.9	9
52	Molecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 783-791	7.9	10
51	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. <i>Nature Medicine</i> , <b>2018</b> , 24, 463-473	50.5	86
50	The Impact of Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 82-88	8.9	210
49	Long-Acting Somatostatin Analog Therapy Differentially Alters Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 223-227	8.9	34
48	Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200649	3.7	4

47	Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through Image Correlation Spectroscopy. <i>Journal of Visualized Experiments</i> , <b>2018</b> ,	1.6	3
46	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 41, 114-121	5.1	51
45	CSIG-25. EPIDERMAL GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN MISSENSE MUTATION A289V AS A DRIVER OF GLIOBLASTOMA INVASION AND PROLIFERATION. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi48-vi48	1	78
44	ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi24-vi24	1	1
43	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 1209-1217	3.5	80
42	Bridging Bio-Nano Science and Cancer Nanomedicine. <i>ACS Nano</i> , <b>2017</b> , 11, 9594-9613	16.7	222
41	Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. <i>Experimental Hematology</i> , <b>2017</b> , 54, 31-39	3.1	13
40	Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 695-707	19.4	69
39	Evolution of anti-HER2 therapies for cancer treatment. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 59, 1-21	14.4	52
38	Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 974-80	8.9	18
37	and Evaluation of Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy. <i>Theranostics</i> , <b>2016</b> , 6, 2225-2234	12.1	8
36	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2-Current Standards and the Path Toward Global Standardization. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1148-57	8.9	19
35	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. <i>Nature Neuroscience</i> , <b>2016</b> , 19, 798-806	25.5	62
34	An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 1741-57	16.6	32
33	Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 646-51	8.9	21
32	Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. <i>Molecular Immunology</i> , <b>2015</b> , 67, 75-88	4.3	30
31	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. <i>Journal of Clinical Neuroscience</i> , <b>2015</b> , 22, 1889-94	2.2	62
30	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144559	3.7	38

29	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1141-51	6.1	55
28	Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. <i>Oncotarget</i> , <b>2015</b> , 6, 38166-80	3.3	13
27	Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. <i>Cancer Research</i> , <b>2014</b> , 74, 4470-81	10.1	59
26	Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia. <i>Nuclear Medicine and Biology</i> , <b>2014</b> , 41, 419-25	2.1	6
25	Detection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies. <i>Nuclear Medicine and Biology</i> , <b>2014</b> , 41, 229-37	2.1	18
24	<sup>18</sup> F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. <i>Urology</i> , <b>2014</b> , 83, 393-8	1.6	33
23	In vivo imaging of cellular proliferation in renal cell carcinoma using <sup>18</sup> F-fluorothymidine PET. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , <b>2014</b> , 2, 3-11	0.7	5
22	Pharmacodynamic analysis of tumour perfusion assessed by <sup>15</sup> O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. <i>EJNMMI Research</i> , <b>2012</b> , 2, 31	3.6	7
21	Antibody therapy of cancer. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 278-87	31.3	1519
20	A simplified protocol for the automated production of succinimidyl 4-[ <sup>18</sup> F]fluorobenzoate on an IBA Synthera module. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2011</b> , 54, 671-673	1.9	16
19	Synthesis of 2-[(4-[ <sup>18</sup> F]Fluorobenzoyloxy)methyl]-1,4-naphthalenedione from 2-hydroxymethyl 1,4-naphthoquinone and 4-[ <sup>18</sup> F]fluorobenzoic acid using dicyclohexyl carbodiimide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2011</b> , 54, 788-794	1.9	5
18	Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 347-53	8.8	29
17	PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 1451-7	8.9	66
16	PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 1593-600	8.9	72
15	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. <i>Blood</i> , <b>2008</b> , 112, 3900-3900	2.2	1
14	A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3286-92	12.9	59
13	Hypoxia positron emission tomography imaging with <sup>18</sup> F-fluoromisonidazole. <i>Seminars in Nuclear Medicine</i> , <b>2007</b> , 37, 451-61	5.4	244
12	F-18 labelled N,N-bis-haloethylamino-phenylsulfoxides: a new class of compounds for the imaging of hypoxic tissue. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2006</b> , 49, 1089-1103	1.9	11

11	Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 410-8	8.9	122
10	Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. <i>Cancer Immunity</i> , <b>2005</b> , 5, 3		9
9	A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 1639-47	12.9	227
8	<sup>11</sup> C labelling of AG957B potential tyrophostin radiotracer for PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2002</b> , 45, 157-165	1.9	5
7	Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system. <i>Cancer Immunology, Immunotherapy</i> , <b>2001</b> , 50, 102-8	7.4	9
6	Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. <i>Cancer Immunology, Immunotherapy</i> , <b>2001</b> , 50, 241-50	7.4	27
5	Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. <i>International Journal of Cancer</i> , <b>2001</b> , 94, 645-51	7.5	54
4	Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 51, 177-80	3.8	28
3	CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA. <i>Journal of Urology</i> , <b>2001</b> , 166, 825-830	2.5	157
2	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. <i>FEBS Journal</i> , <b>2000</b> , 267, 2505-15		86
1	Antibody-drug conjugates: beyond current approvals and potential future strategies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 252-277	2.5	1